Clinical trials: Hematological Malignancies
Hematologic Disease and Disorders, Donors
Screening for Hematology Branch Protocols
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Trial name
- NCT00001620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia, Non Hodgkin's Lymphoma
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
The purpose of this study is to assess early treatment failure within 100 days and to assess the effect of this regimen on engraftment, GVHD, immune recovery, relapse of malignancy and survival.
- Conditions
- Leukemia, Non Hodgkin's Lymphoma, Aplastic Anemia
- Trial name
- NCT00038779
- Testing
- Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic Neoplasms, Hematopoietic Malignancy
Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation
The main purpose of this study is to determine if a novel peer support intervention (STEPP) is feasible among patients undergoing hematopoietic stem cell transplantation (HSCT).
- Trial name
- STEPP (NCT06010017)
- Testing
- STEPP Intervention
- Where
- 2 sites in United States
- Volunteers
- 136 people
- Sponsor
- Brigham and Women's Hospital
Blood Cancer
Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy
The purpose of this study is to determine which of two approaches is helpful to support caregivers of patients undergoing Hematopoietic Stem Cell Transplant (HSCT) or Chimeric Antigen Receptors (CAR) T-cell therapy at Seidman…
- Trial name
- NCT04390542
- Testing
- Psychoeducation
- Sponsor
- Case Comprehensive Cancer Center
Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive T-cell hematological maliganacies
- Conditions
- Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Lymphoma, Acute T Cell Leukemia
- Trial name
- NCT04828174
- Testing
- anti-TRBC1 CAR-T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease
Host Dendritic Cells in Allograft Patients
The purpose of this study is to assess preliminary efficacy and to determine the safety and feasibility of ex vivo generated dendritic cell (HDC) infusion with and without donor lymphocyte infusion (DLI) after allogeneic stem…
- Conditions
- Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Chronic Lymphocytic Lymphoma
- Trial name
- NCT00935597
- Testing
- MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Solid Tumors, Hematologic Malignancies
Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.
- Trial name
- NCT02457962
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- Mayo Clinic
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with azacitidine.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01110473
- Testing
- ABT-348, ABT-348 and azacitidine
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hematopoietic Malignancy, Relapse/Recurrence
TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
About 33% of patients with myeloid or lymphoid malignancies experience relapse with HLA loss after haplo-HSCT. Due to the specificity of HLA-loss relapse, the 2019 European Society for Blood and Marrow Transplantation (EBMT)…
- Conditions
- Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06125483
- Testing
- Umbilical Cord Blood Transplantation
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Malignant Disease, Solid Tumor
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in…
- Conditions
- Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT03560882
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Joaquina Baranda
Acute Myeloid Leukaemia (AML), Leukemia
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp.
- Conditions
- Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
- Trial name
- NCT07148180
- Testing
- Tagraxofusp, Azacitidine (AZA), Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Jacqueline Garcia, MD
Poor Thymic Function, Immunodeficiency
Expanded Access Protocol Thymus Transplantation
The primary purpose is to provide access for patients who have immunodeficiency or severe autoimmune disease related to poor thymic function to cultured thymus tissue for implantation.
- Conditions
- Poor Thymic Function, Immunodeficiency, Athymia, Immunoreconstitution
- Trial name
- NCT02274662
- Testing
- Cultured Thymus Tissue, Blood Draw, Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
- Volunteers
- 11 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Acute Leukemias, Chronic Leukemias
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age.
- Conditions
- Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT01339988
- Testing
- Busulfan/Cyclophosphamide
- Volunteers
- 10 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hematological Malignancies
M-2018-334 in Hematological Malignancies
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
- Trial name
- HAPLO2022 (NCT06225050)
- Testing
- CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Miltenyi Biomedicine GmbH
Myeloproliferative Neoplasms of, Polycythemia Vera
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms.
- Conditions
- Myeloproliferative Neoplasms of, Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Trial name
- NCT01520220
- Testing
- LY2784544
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Hematologic Diseases, Hematologic Malignancy
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
This is a Phase II trial testing disease-specific myeloablative conditioning regimens for preparatory cytoreduction of patients receiving allogeneic HLA-compatible related or unrelated transplants of GCSF-mobilized peripheral…
- Conditions
- Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- 2019-KOE-001 (NCT04282174)
- Testing
- CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Baptist Health South Florida
Polycythemia Vera, Essential Thrombocytosis
Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
The three main chronic myeloproliferative disorders are polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).
- Conditions
- Polycythemia Vera, Essential Thrombocytosis, Idiopathic Myelofibrosis, Neutrophils
- Trial name
- NCT00433862
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Thrombocytopenia
Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia
The purpose of the research project is to collect one blood sample from participants who are affected by very low platelets as a result of their condition or their treatment.
- Trial name
- NCT06824727
- Testing
- Baseline cell blood counts
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Acute Biphenotypic Leukemia, Acute Leukemia
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
This phase II trial tests how well removing CD45RA positive naive T cells works to prevent graft versus host disease in older patients undergoing standard of care allogeneic hematopoietic stem cell transplantation for the…
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT07819396
- Testing
- Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.